MAP2K1 and thyroid gland carcinoma: In the LUAD cohort, EGFR and MEK1 rank highly; they represent targets of an approved lung cancer drug and compounds under investigation in several clinical trials.27, 28, 29, 30 Similarly, MET and RET are among the high-scoring Tclin kinases for thyroid cancer.